Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise

Entera Bio (ENTX) received an 'Outperform' rating and $9 price target from Leerink Partners. The company's lead drug, EB613, is in development for osteoporosis and has completed Phase 2 trials. Entera recently raised $275M in funding and plans to initiate Phase 3 trials in late 2026, with data expected in 2028. ENTX was trading at $3.03 per share as of September 17, 2026.

Entera Bio (ENTX) raised $275M in an oversubscribed private placement, funding Phase 3 trials for EB613, its oral osteoporosis treatment, and extending its cash runway to 2030. Shares rose despite dilution concerns, with BVF Partners leading the investment. The FDA accepted the Phase 3 protocol, and analysts project a loss for Q2 2024 with a $9 price target.

Entera Bio Ltd. (NASDAQ: ENTX) reported Q2 2026 EPS loss of $0.14 versus a $0.08 consensus estimate, with net loss widening to $7.3 million from $2.7 million a year earlier, driven mainly by a $2.7 million non-cash warrant fair value remeasurement. The company also closed an oversubscribed $275 million private placement to fund EB613 Phase 3 NDA work through 2030.

Entera Bio Ltd. (ENTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Entera Announces Second Quarter 2026 Financial Results and Business Updates U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women wi

Greenberg Traurig advised Entera Bio Ltd. (NASDAQ: ENTX) on an oversubscribed $275 million private placement PIPE. The company said the proceeds extend its cash runway into 2030 and fund Phase 3 registrational studies for EB613, an oral PTH (1-34) peptide tablet for osteoporosis. Arx Capital Markets data cited the deal as a record Israeli biotech PIPE.

Entera Bio (ENTX) shares rose after the company priced a large securities offering to fund EB613’s Phase 3 osteoporosis program. Entera said the financing should extend its cash runway into 2030 and support planned FDA application. It will sell 122.96M shares at $2.04 and pre-funded warrants for up to 11.84M shares. Analysts expect an Aug. 11 loss of 8 cents/share.